Phase I – Bioequivalence

295 trials 18 recruiting

Filter these 295 trials by condition, country, sponsor and more.

Open in Search →

Bioequivalence study on aqueous humour concentrations of active ingredients after topical application of LEVIOSA® versus F2904. Randomized,… Ended

2023-503722-39-00 Cataract 2024-04-22
Bioequivalence of Progesterone Vaginal Insert 100 mg in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended

2022-502614-82-00 No medical condition. 2024-04-18
RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 M… Ended

2023-508747-49-00 Antimigraine 2024-04-10
Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fed Conditions Ended

2023-504259-29-00 No medical condition 2024-03-18
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetr… Ended

2023-504355-28-03 Healthy volunteers 2024-03-14
Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a sing… Ended

2023-507599-34-00 healthy volunteer 2024-03-11
A Single Dose, Fed state, Crossover Replicate, Bioequivalence Study of Naproxen 500 mg/ Esomeprazole 20 mg modified-release tablets (Antibio… Ended

2023-508621-27-00 healthy subjects 2024-03-05
Bioequivalence of Cladribine 10 mg from two different products Ended

2023-508656-19-00 No therapeutic indication in the current trial with hea 2024-03-01
A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetyls… Ended

2023-509841-12-00 increased blood clotting 2024-02-28
A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokine… Ended

2023-509862-39-00 Healthy volunteers 2024-02-23
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaft… Ended

2023-508115-23-00 Cystic Fibrosis 2024-02-20
A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY… Ended

2023-507877-17-00 Not applicable, Healthy Volunteers 2024-02-12
AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TAB… Ended

2023-506596-10-00 Study performed on healthy volunteers. 2024-01-31
Bioequivalence of Apixaban 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended

2023-506844-18-00 No medical condition. 2024-01-10
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2023-508339-29-00 No medical condition. 2023-12-26
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended

2023-504516-15-00 No medical condition. 2023-12-18
In vivo bioequivalence study of a new clobetasol propionate 0.05% topical cream compared to DERMOVAL® 0.05% cream using the skin blanching b… Ended

2023-504879-24-00 corticosteroid-sensitive dermatosis 2023-12-12
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagli… Ended

2023-506408-18-00 diabetes 2023-11-21
A bioequivalence vasoconstriction study comparing two clobetasol propionate 0.5 mg/g ointments after skin application in healthy adult human… Ended

2023-504707-87-00 Localized, therapy-resistant inflammatory skin diseases 2023-11-20
Randomised, crossover bioequivalence clinical trial of linagliptin 5 mg film-coated tablets, after a single oral dose administration to heal… Ended

2023-506047-41-00 diabetes 2023-11-07
A single dose, randomized, open-label, three-way crossover study to assess bioequivalence of paracetamol orodispersible tablets 500 mg vs Ap… Ended

2023-504815-34-00 Healthy volunteers under fasting conditions 2023-10-30
A comparative bioavailability of reformulated ibuprofen 2% and 4% oral suspensions (Berlin Chemie AG) and reference ibuprofen (Nurofen®) 200… Ended

2023-503703-28-00 In this study will be no subjects involved with any spe 2023-10-25
OPEN LABEL, FOUR-PERIOD, TWO-SEQUENCE, FULLY-REPLICATED, RANDOMIZED, SINGLE DOSE COMPARATIVE STUDY TO ASSESS BIOEQUIVALENCE OF Polypill AAR … Ended

2023-505572-30-00 Study performed on healthy volunteers 2023-10-24
An open label, randomized, four-period, four-sequence single dose, crossover trial in healthy volunteers to determine the relative bioavaila… Ended

2022-502420-51-00 No therapeutic indication in the current trial with hea 2023-10-23